Etoposide

Generic Name: Etoposide

Brand Names: Etopophos, Toposar, Vepesid

Drug Type: Small Molecule

Chemical Formula: C_₂₉H_₃₂O_₁₃

CAS Number: 33419-42-0

Unique Ingredient Identifier: 6PLQ3CP4P3

Background: A semisynthetic derivative of podophyllotoxin that exhibits antitumor activity. Etoposide inhibits DNA synthesis by forming a complex with topoisomerase II and DNA. This complex induces breaks in double stranded DNA and prevents repair by topoisomerase II binding. Accumulated breaks in DNA prevent entry into the mitotic phase of cell division, and lead to ce...

Indication: For use in combination with other chemotherapeutic agents in the treatment of refractory testicular tumors and as first line treatment in patients with small cell lung cancer. Also used to treat other malignancies such as lymphoma, non-lymphocytic leukemia, and glioblastoma multiforme.

Associated Conditions: Acute Lymphoblastic Leukaemias (ALL), Acute Myeloid Leukemia, Advanced Hodgkin's Lymphoma, Ewing's Sarcoma, Gestational Trophoblastic Neoplasia, Merkel cell cancer, Multiple Myeloma (MM), Neuroblastoma (NB), Neuroendocrine Tumors, Non-Hodgkin's Lymphomas, Non-Small Cell Lung Cancer (NSCLC), Osteosarcoma, Ovarian Cancer, Prostate Cancer, Retinoblastoma, Small Cell Lung Cancer (SCLC), Wilms' tumor, Locally advanced Thymoma, Metastatic Thymic Cancer, Refractory Sarcoma, Refractory Testicular cancer

Associated Therapies: -

Clinical Trials

Surgery in Treating Children With Neuroblastoma

Phase 3

Completed

Conditions: Neuroblastoma

Interventions: Procedure: conventional surgery
Biological: filgrastim
Radiation: radiation therapy
Biological: sargramostim
Drug: carboplatin
Drug: cyclophosphamide
Drug: doxorubicin hydrochloride
Drug: etoposide
Procedure: adjuvant therapy

First Posted Date: 2003-01-27

Last Posted Date: 2017-03-13

Lead Sponsor: Children's Oncology Group

Target Recruit Count: 968

Registration Number: NCT00003119

Locations: 🇺🇸
University of Chicago Cancer Research Center, Chicago, Illinois, United States
🇺🇸
Rush University Medical Center, Chicago, Illinois, United States
🇺🇸
University of Illinois Medical Center, Chicago, Illinois, United States

and more 231 locations

Combination Chemotherapy Alone or With Radiation Therapy in Treating Children With Kidney Cancer

Phase 3

Completed

Conditions: Kidney Cancer

Interventions: Biological: dactinomycin
Drug: vincristine sulfate
Biological: filgrastim
Drug: doxorubicin hydrochloride
Procedure: conventional surgery
Drug: cyclophosphamide
Radiation: radiation therapy
Drug: etoposide

First Posted Date: 2003-01-27

Last Posted Date: 2021-02-25

Lead Sponsor: Children's Oncology Group

Target Recruit Count: 3031

Registration Number: NCT00002611

Locations: 🇺🇸
Children's Hospital Central California, Madera, California, United States
🇺🇸
Maine Children's Cancer Program, Scarborough, Maine, United States
🇺🇸
Rush-Presbyterian-St. Luke's Medical Center, Chicago, Illinois, United States

and more 231 locations

Combination Chemotherapy in Treating Patients With Previously Untreated Advanced Hodgkin's Lymphoma

Phase 3

Conditions: Lymphoma

First Posted Date: 2003-01-27

Last Posted Date: 2013-09-20

Lead Sponsor: Mount Vernon Cancer Centre at Mount Vernon Hospital

Target Recruit Count: 850

Registration Number: NCT00041210

Locations: 🇬🇧
Pinderfields General Hospital, Wakefield, Scotland, United Kingdom
🇬🇧
Aintree University Hospital, Liverpool, England, United Kingdom
🇬🇧
City Hospital - Birmingham, West Bromwich, England, United Kingdom

and more 34 locations

Combination Chemotherapy in Treating Patients With Stage I, II, or IIIA Non-small Cell Lung Cancer That Has Been Surgically Removed

Phase 3

Conditions: Lung Cancer

First Posted Date: 2003-01-27

Last Posted Date: 2013-09-20

Lead Sponsor: European Institute of Oncology

Target Recruit Count: 750

Registration Number: NCT00003053

Locations: 🇮🇹
Ospedale San Filippo Neri, Rome, Italy
🇮🇹
Universita Degli Studi di Bari Policlinico, Bari, Italy
🇮🇹
Ospedale Oncologico A. Businco, Cagliari, Italy

and more 82 locations

Combination Chemotherapy in Treating Patients Who Have Extensive-Stage Small Cell Lung Cancer

Phase 3

Conditions: Lung Cancer

First Posted Date: 2003-01-27

Last Posted Date: 2013-09-17

Lead Sponsor: Commissie Voor Klinisch Toegepast Onderzoek

Target Recruit Count: 250

Registration Number: NCT00003696

Locations: 🇳🇱
Vrije Universiteit Medisch Centrum, Amsterdam, Netherlands

Combination Chemotherapy Followed by Surgery and Peripheral Stem Cell or Bone Marrow Transplantation in Treating Infants With Newly Diagnosed Neuroblastoma

Phase 2

Completed

Conditions: Neuroblastoma

First Posted Date: 2003-01-27

Last Posted Date: 2013-09-17

Lead Sponsor: European Infant Neuroblastoma Study Group - 1999

Registration Number: NCT00025649

Locations: 🇸🇪
Ostra Sjukhuset, Gothenburg, Sweden
🇫🇷
Centre Hospitalier Regional de Purpan, Toulouse, France
🇳🇴
Rikshospitalet University Hospital, Oslo, Norway

and more 8 locations

Combination Chemotherapy in Treating Infants With Newly Diagnosed Neuroblastoma

Phase 2

Completed

Conditions: Neuroblastoma

First Posted Date: 2003-01-27

Last Posted Date: 2013-09-17

Lead Sponsor: European Infant Neuroblastoma Study Group - 1999

Registration Number: NCT00025610

Locations: 🇨🇭
Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland
🇦🇹
St. Anna Children's Hospital, Vienna, Austria
🇧🇪
Universitair Ziekenhuis Gent, Ghent, Belgium

and more 9 locations

Combination Chemotherapy Followed by Surgery in Treating Infants With Newly Diagnosed Neuroblastoma

Phase 2

Completed

Conditions: Neuroblastoma

First Posted Date: 2003-01-27

Last Posted Date: 2013-09-17

Lead Sponsor: European Infant Neuroblastoma Study Group - 1999

Registration Number: NCT00025623

Locations: 🇳🇴
Rikshospitalet University Hospital, Oslo, Norway
🇨🇭
Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland
🇫🇷
Centre Hospitalier Regional de Purpan, Toulouse, France

and more 8 locations

Combination Chemotherapy With or Without Hyperthermia Therapy in Treating Patients With Soft Tissue Sarcoma

Phase 3

Completed

Conditions: Sarcoma

First Posted Date: 2003-01-27

Last Posted Date: 2013-09-17

Lead Sponsor: European Organisation for Research and Treatment of Cancer - EORTC

Target Recruit Count: 340

Registration Number: NCT00003052

Locations: 🇩🇪
Robert Roessle Comprehensive Cancer Center at University of Berlin - Charite Campus Buch, Berlin, Germany
🇩🇪
Universitaetsklinikum Hamburg-Eppendorf, Hamburg, Germany
🇩🇪
Universitaetsklinikum Essen, Essen, Germany

and more 1 locations

Chemotherapy Followed by Radiation Therapy and Peripheral Stem Cell Transplant Compared With Chemotherapy Plus Interferon Alfa in Treating Patients With Stage III or Stage IV Mantle Cell Lymphoma

Phase 3

Conditions: Lymphoma

First Posted Date: 2003-01-27

Last Posted Date: 2013-09-17

Lead Sponsor: German Low Grade Lymphoma Study Group

Registration Number: NCT00016887

Locations: 🇧🇪
AZ Sint-Jan, Brugge, Belgium
🇮🇹
Ospedale Civile Alessandria, Alessandria, Italy

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy